Would Biden’s ‘Advanced Research’ Projects Mesh Well At NIH?
HHS Secretary Becerra answers questions about the scope of the proposed ARPA-H agency; more to come during NIH budget hearing.
You may also be interested in...
White House Science Advisor Shuffle Could Affect ARPA-H – And ‘March In’ Debate
Former NIH Director Francis Collins is returning to government as the top scientific advisor to President Biden. The post is temporary but comes at a critical time for the attempt to launch a new health innovation agency – and maybe for the direction of administrative pricing actions.
NIH Director Collins’ Departure May Revive Patent March-In Debate
Confirmation hearing for successor will present opportunity to press the Biden administration on the patent march-in issue, but a policy change seems unlikely—unless the President feels a strong need to act on drug pricing in the absence of legislation.
FDA’s Pazdur Believes ‘Advanced Research’ Project Could Address Trial ‘Wastefulness’
ARPA-H could be a solution to some of FDA’s long-running complaints about US clinical trial infrastructure, the agency's cancer chief says.